Directorate Change

16 June 2020

ABCAM PLC

("Abcam" or "the Group")

Directorate Change

Jonathan Milner to step down at next AGM in November 2020

Abcam plc (AIM: ABC) today announces that Jonathan Milner, co-founder and Non-Executive Deputy Chairman of Abcam, has informed the Board that he will not stand for re-election at the Group's next Annual General Meeting, to allow him to focus on his growing portfolio of early stage company investments. After stepping down as CEO of Abcam in 2014, Jonathan founded Meltwind Advsiory LLP, where he has had the opportunity to invest in and help foster the growth of over 40 early stage companies. Today, Jonathan is Chairman of Axol Bioscience Ltd, Cambridge Allergy Ltd and PhoreMost Ltd; and a non-executive director of Healx Ltd, Start Codon Ltd and Syndicate Room Group Ltd as well as the charity The Evolution Education Trust.

Alan Hirzel, Chief Executive Officer of Abcam, said:

"Jonathan's exceptional vision and ambition created Abcam in 1998.  I have been inspired by his energy and dedication to science from our first meeting eight years ago through to the work we have done together to build Abcam into the global leader it is today.  Britain needs even more entrepreneurs like Jonathan, and I wish him well as he mentors and develops others through his growth capital investments."

Peter Allen, Chairman of Abcam, added:

"Since I joined Abcam as Chairman in 2018, Jonathan has been an exceptional colleague and an integral part of the Board. On behalf of everyone at Abcam, I would like to thank Jonathan for his commitment and leadership over the years.  I wish him every success in the future."

Jonathan Milner, Non-Executive Deputy Chairman of Abcam, commented:

"Abcam is an extraordinary company and has been a significant part of my life for over two decades. I leave my position as Deputy Chairman knowing the business is in strong hands and is positioned for an exciting future. I would like to take this opportunity to thank everyone who has supported me, and been involved in the success of the company since its inception.  I remain a great supporter and significant shareholder in Abcam, and look forward to seeing Alan and the team continue to grow and scale the business."

Abcam plc

James Staveley VP, Investor Relations +44 (0) 1223 696 000

J.P. Morgan Cazenove - Nominated Adviser & Corporate Broker

+44 (0) 20 7742 4000

James Mitford / Hemant Kapoor

Numis - Joint Corporate Broker

+44 (0) 20 7260 1000

Garry Levin / Duncan Monteith

Media enquiries:

FTI Consulting

+44 (0) 20 3727 1000

Ben Atwell / Natalie Garland-Collins  

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Group offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Some two-thirds of the world's 750,000 life science researchers use Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Group continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 140 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

Please visit www.abcam.com or www.abcamplc.com to find out more.